 |
|
Long-Chain  -3 Fatty Acids for Indicated Prevention of Psychotic DisordersA Randomized, Placebo-Controlled Trial
G. Paul Amminger, MD;
Miriam R. Schäfer, MD;
Konstantinos Papageorgiou, MD;
Claudia M. Klier, MD;
Sue M. Cotton, PhD;
Susan M. Harrigan, MSc;
Andrew Mackinnon, PhD;
Patrick D. McGorry, MD, PhD;
Gregor E. Berger, MD
Arch Gen Psychiatry. 2010;67(2):146-154.
Context The use of antipsychotic medication for the prevention of psychotic disorders is controversial. Long-chain  -3 (omega-3) polyunsaturated fatty acids (PUFAs) may be beneficial in a range of psychiatric conditions, including schizophrenia. Given that -3 PUFAs are generally beneficial to health and without clinically relevant adverse effects, their preventive use in psychosis merits investigation.
Objective To determine whether -3 PUFAs reduce the rate of progression to first-episode psychotic disorder in adolescents and young adults aged 13 to 25 years with subthreshold psychosis.
Design Randomized, double-blind, placebo-controlled trial conducted between 2004 and 2007.
Setting Psychosis detection unit of a large public hospital in Vienna, Austria.
Participants Eighty-one individuals at ultra-high risk of psychotic disorder.
Interventions A 12-week intervention period of 1.2-g/d -3 PUFA or placebo was followed by a 40-week monitoring period; the total study period was 12 months.
Main Outcome Measures The primary outcome measure was transition to psychotic disorder. Secondary outcomes included symptomatic and functional changes. The ratio of -6 to -3 fatty acids in erythrocytes was used to index pretreatment vs posttreatment fatty acid composition.
Results Seventy-six of 81 participants (93.8%) completed the intervention. By study's end (12 months), 2 of 41 individuals (4.9%) in the -3 group and 11 of 40 (27.5%) in the placebo group had transitioned to psychotic disorder (P = .007). The difference between the groups in the cumulative risk of progression to full-threshold psychosis was 22.6% (95% confidence interval, 4.8-40.4). -3 Polyunsaturated fatty acids also significantly reduced positive symptoms (P = .01), negative symptoms (P = .02), and general symptoms (P = .01) and improved functioning (P = .002) compared with placebo. The incidence of adverse effects did not differ between the treatment groups.
Conclusions Long-chain -3 PUFAs reduce the risk of progression to psychotic disorder and may offer a safe and efficacious strategy for indicated prevention in young people with subthreshold psychotic states.
Trial Registration clinicaltrials.gov Identifier: NCT00396643
Author Affiliations: Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria (Drs Amminger, Schäfer, Papageorgiou, and Klier); Orygen Research Centre, Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia (Drs Amminger, Cotton, Mackinnon, and McGorry and Ms Harrigan); and Department of Research and Education, The Schlössli Clinic, Oetwil am See, Switzerland (Dr Berger).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
This Month in Archives of General Psychiatry
Arch Gen Psychiatry. 2010;67(2):109.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Preventing progression to first-episode psychosis in early initial prodromal states
Bechdolf et al.
Br. J. Psychiatry 2012;200:22-29.
ABSTRACT
| FULL TEXT
Intervening in clinical research to prevent the onset of psychoses: conflicts and obligations
Lysaght et al.
J. Med. Ethics 2011;0:medethics-2011-100008v1-medethics-2011-100008.
Disease Prediction in the At-Risk Mental State for Psychosis Using Neuroanatomical Biomarkers: Results From the FePsy Study
Koutsouleris et al.
Schizophr Bull 2011;0:sbr145v1-sbr145.
ABSTRACT
| FULL TEXT
Risk, Disorder and Diagnosis
Yung
Aust N Z J Psychiatry 2011;45:915-919.
FULL TEXT
The Use of Omega-3 Fatty Acids in Mental Illness
Goren and Tewksbury
Journal of Pharmacy Practice 2011;24:452-471.
ABSTRACT
| FULL TEXT
Rationale and Baseline Characteristics of PREVENT: A Second-Generation Intervention Trial in Subjects At-Risk (Prodromal) of Developing First-Episode Psychosis Evaluating Cognitive Behavior Therapy, Aripiprazole, and Placebo for the Prevention of Psychosis
Bechdolf et al.
Schizophr Bull 2011;37:S111-S121.
ABSTRACT
| FULL TEXT
'Prodromal Diagnosis' of Psychosis: An Impartial Commentary
Jorm
Aust N Z J Psychiatry 2011;45:520-523.
FULL TEXT
Early Recognition and Disease Prediction in the At-Risk Mental States for Psychosis Using Neurocognitive Pattern Classification
Koutsouleris et al.
Schizophr Bull 2011;0:sbr037v1-sbr037.
ABSTRACT
| FULL TEXT
Emotion Recognition in Individuals at Clinical High-Risk for Schizophrenia
Amminger et al.
Schizophr Bull 2011;0:sbr015v1-sbr015.
ABSTRACT
| FULL TEXT
Rebooting Psychotherapy Research and Practice to Reduce the Burden of Mental Illness
Kazdin and Blase
Perspectives on Psychological Science 2011;6:21-37.
ABSTRACT
| FULL TEXT
Developmental Vitamin D Deficiency and Risk of Schizophrenia: A 10-Year Update
McGrath et al.
Schizophr Bull 2010;36:1073-1078.
ABSTRACT
| FULL TEXT
Young Rural People at Risk for Schizophrenia: Time for Mental Health Services to Translate Research Evidence into Best Practice of Care
Stain et al.
Aust N Z J Psychiatry 2010;44:872-882.
ABSTRACT
| FULL TEXT
Omega-3s for Prodromal Psychosis
JWatch Psychiatry 2010;2010:2-2.
FULL TEXT
Chapter 14 Early interventions for people with psychotic disorders
Power and McGorry
Oxford Textbook of Community Mental Health 2010;1:med-9780199565498-chapter-med-9780199565498-chapter.
ABSTRACT
| FULL TEXT
RAPID RESPONSES TO THIS ARTICLE
Fish Oil to Prevent Psychosis
Scott W Woods
Arch Gen Psychiatry Online, 23 Feb 2010.
TEXT
Omega-3 Fatty Acid Deficiency as a Risk Factor for Schizophrenia
Robert K. McNamara
Arch Gen Psychiatry Online, 9 Mar 2010.
TEXT
|
